Drugs / mosnodenvir
mosnodenvir
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05201937 | Feb → Dec 2022 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 24 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT05201794 | Feb 2023 → Jun 2024 | dengue disease | Janssen Research & Development, LLC | Terminated | Missed primary Stop: Business |
| Phase 2 | NCT05048875 | Feb 2022 → May 2023 | dengue disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Met primary |
| Phase 2 | NCT04906980 | Jan → Sep 2022 | dengue disease | Janssen Research & Development, LLC | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04480736 | Jul 2020 → Sep 2027 | — | Janssen Research & Development, LLC | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mosnodenvir | “receive oral mosnodenvir once daily” PMID 41297006 ↗ Nov 2025 |
| Known as | JNJ-1802 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314530 ↗ |
| Known as | JNJ-64281802 | “The investigational study drug, JNJ-64281802, is being developed for the prevention and treatment of dengue infection.” NCT05048875 ↗ |
| Modality | Small molecule | — CHEMBL5314530 ↗ |
| Route | Oral | “JNJ-64281802 high dose will be administered orally.” NCT04480736 ↗ |